Condition: Select Advanced Solid Tumors · Sponsor: CDR-Life AG
CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A\*02:01 tissue marker and whose cancer is positive for MAGE-A4.
This description comes directly from the study's public registry record.
Dimitrios Chondros Chief Medical Officer, CDR-Life · +41 44 515 7025 · CDR404-001_Study@CDR-Life.com
Always discuss trial participation with your own doctor first.
| University of Miami | Miami, Florida, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Providence Cancer Institute | Portland, Oregon, United States | Recruiting |
| Pennsylvania Hospital | Philadelphia, Pennsylvania, United States | Recruiting |
| Universitair Ziekenhuis Antwerpen | Antwerp, Belgium | Recruiting |
| Institut Jules Bordet | Brussels, Belgium | Recruiting |
| Cliniques Universitaires Saint-Luc, UCL Ouvain | Brussels, Belgium | Recruiting |
| Universitair Ziekenhuis Gent | Ghent, Belgium | Recruiting |
| Rigshospitalet | Copenhagen, Denmark | Recruiting |
| Istituto Clinico Humanitas | Milan, Italy | Recruiting |
| Isituto Europeo di Oncologia (IEO) | Milan, Italy | Recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona, Spain | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06402201